Latest Us Market News

Aristocrat Leisure reported a robust first half FY2025 with 9% revenue growth and a 6% rise in normalised NPATA, driven by strategic acquisitions and market share gains. The company returned $533 million to shareholders while positioning for sustained growth across its gaming portfolio.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Austco Healthcare has renewed its preferred supplier agreement with a major US healthcare provider, continuing supply of its Tacera nurse call systems to 180 hospitals across 30 states. This extension builds on a lucrative five-year partnership worth over A$49 million.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Acrux Limited, partnering with TruPharma, has introduced its Dapsone 7.5% Gel in the US, featuring a unique tube packaging that aims to improve patient convenience and reduce environmental impact.

Guzman y Gomez has unveiled an ambitious expansion and margin improvement plan at the 2025 Macquarie Australia Conference, reaffirming its FY25 guidance and spotlighting strong franchise growth and operational excellence.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

SciDev Limited reported a robust Q3 FY25 with revenue rising 10% and EBITDA tripling, driven by strategic US market expansion and a landmark PFAS remediation contract despite ongoing market challenges.

Zip Co Limited reported robust April trading with over 40% year-on-year growth in US total transaction value, underpinning a strong profitability turnaround and reaffirming its FY25 cash EBTDA guidance of at least $153 million.